Loading…
Prime Medicine, Inc. is projected to rise to $3.34 by 2027, a +14% move from its current price of $2.92. PRME is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $2.80 | $2.92 | $3.04 | -0.05% |
| Aug 3 | $2.76 | $2.92 | $3.09 | -0.10% |
| Aug 4 | $2.72 | $2.92 | $3.12 | -0.16% |
| Aug 5 | $2.69 | $2.91 | $3.15 | -0.21% |
| Aug 6 | $2.67 | $2.91 | $3.18 | -0.26% |
| Aug 7 | $2.64 | $2.91 | $3.21 | -0.31% |
| Aug 8 | $2.62 | $2.91 | $3.23 | -0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.62 | $2.91 | $3.23 | -0.36% |
| Week 2 | $2.50 | $2.90 | $3.36 | -0.73% |
| Week 3 | $2.41 | $2.89 | $3.46 | -1.09% |
| Week 4 | $2.33 | $2.88 | $3.55 | -1.45% |
| Week 5 | $2.27 | $2.87 | $3.63 | -1.80% |
| Week 6 | $2.21 | $2.86 | $3.69 | -2.16% |
| Week 7 | $2.16 | $2.85 | $3.76 | -2.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Prime Medicine, Inc. is a biotechnology company focused on delivering genetic medicines by deploying gene editing technology in the United States. Its work centers on PM359, the lead therapeutic candidate for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trials.
PM577 targets Wilson Disease and is in preclinical studies, and PM647 aims to treat a genetic disorder caused by SERPINA1 mutations, with associated liver implications.
The company also pursues vivo programs targeting liver diseases and Cystic Fibrosis programs. Prime Medicine describes Prime Editing technology as comprising programmable DNA binding domains, a RT domain that copies the edited DNA sequence directly into the target site, and pegRNA containing a spacer that provides a target genomic address for the Prime Editor. It was incorporated in 2019 and is headquartered in Cambridge, Massachusetts, with research collaborations and licensing relationships with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam.
Prime Medicine, Inc. (PRME) is a biotechnology company trading in the healthcare sector. The stock’s current price is $2.97, and its market capitalization is $536.43M, with a rank of 2927.
The asset operates within Healthcare and has a multi-year price forecast outlining a path from a flat near-term outlook in 2026 to a pronounced bullish trajectory into the 2030s and 2040s. Forecasted averages rise from $2.97 in 2026 to $4.76 in 2030, then climb to higher levels by 2035, 2040, and 2050, with corresponding max prices and ROI figures.
Overall, the outlook projects rising averages and substantial ROI later in the horizon, reflecting a long-run bullish price path while near-term sentiment remains mixed.
A major floor 38.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 58.2% above — a clean break opens room to run.
A major ceiling 77.6% above — clearing it would confirm fresh momentum.
Key PRME support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRME market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.01 | Sell | $3.00 | Sell |
| MA 10 | $3.02 | Sell | $3.08 | Sell |
| MA 20 | $3.38 | Sell | $3.21 | Sell |
| MA 50 | $3.28 | Sell | $3.31 | Sell |
| MA 100 | $3.39 | Sell | $3.41 | Sell |
| MA 200 | $3.72 | Sell | $3.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.25 | Neutral |
| Stoch RSI (14) | 2.13 | Buy |
| CCI (20) | -77.16 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -16.33 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -0.34 | Sell |
| Ultimate (7,14,28) | 30.35 | Neutral |
| Momentum (10) | -0.21 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 3.01 | Sell |
| ADX (14) | 17.58 | Neutral |
| ATR (14) | 0.12 | Info |
Bearish sentiment dominates near-term momentum. RSI14 is 40, and the 50-day simple moving average sits at $3.28 while the 200-day simple moving average sits at $3.81.
The stock trades within a 30-day range of $2.19 to $4.03, indicating a broad swing around the current level. Support is identified at $2.71 and resistance at $4.62, framing a modest range for near-term activity. Annualized volatility stands at 90%, underscoring macro swings in the price path.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.70 | $2.92 | $3.52 | 0% | Neutral | |
| $2.56 | $3.34 | $4.68 | +14% | Neutral | |
| $2.88 | $3.93 | $5.80 | +35% | Bullish | |
| $3.14 | $4.45 | $6.82 | +52% | Bullish | |
| $3.14 | $4.60 | $7.29 | +57% | Bullish | |
| $2.76 | $4.16 | $6.78 | +42% | Bullish | |
| $2.99 | $4.63 | $7.75 | +59% | Bullish | |
| $3.09 | $4.92 | $8.42 | +69% | Bullish | |
| $3.41 | $5.56 | $9.71 | +90% | Bullish | |
| $4.16 | $6.96 | $12.39 | +138% | Bullish | |
| $4.76 | $8.91 | $17.17 | +205% | Bullish | |
| $5.75 | $12.77 | $27.59 | +337% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.70 | $2.92 | $3.56 | +0.00% |
| September 2026 | $2.46 | $2.95 | $3.67 | +1.15% |
| October 2026 | $2.30 | $2.78 | $3.51 | -5.72% |
| November 2026 | $2.16 | $2.64 | $3.37 | -5.18% |
| December 2026 | $2.21 | $2.72 | $3.52 | +3.19% |
Click any year to see its month-by-month PRME forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PRME to range from $2.70 to $3.52 through 2026. The $2.92 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The PRME price prediction for 2027 points to an average of $3.34 (low $2.56, high $4.68) — a potential gain of +14% on today's $2.92. Price action looks broadly range-bound.
In 2028, PRME is projected to trade between $2.88 and $5.80, averaging $3.93 — a potential gain of +35% from today's $2.92. That is up +18% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Prime Medicine, Inc.'s 2029 outlook centres on $4.45, within a $3.14 to $6.82 range. That is up +13% on the projected 2028 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2030, PRME could reach as high as $7.29, with a base case around $4.60 and support toward $3.14 — roughly +57% from $2.92. Buyers look set to stay in control over this stretch.
Expect PRME to range from $2.76 to $6.78 through 2031. The $4.16 average target implies a +42% move from current prices. That is -10% versus the projected 2030 average. Momentum favours further upside here.
The PRME price prediction for 2032 points to an average of $4.63 (low $2.99, high $7.75) — a potential gain of +59% on today's $2.92. Buyers look set to stay in control over this stretch.
In 2033, PRME is projected to trade between $3.09 and $8.42, averaging $4.92 — a potential gain of +69% from today's $2.92. That is up +6% on the projected 2032 average. Momentum favours further upside here.
Prime Medicine, Inc.'s 2034 outlook centres on $5.56, within a $3.41 to $9.71 range. That is up +13% on the projected 2033 average. That marks a +90% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, PRME could reach as high as $12.39, with a base case around $6.96 and support toward $4.16 — roughly +138% from $2.92. Momentum favours further upside here.
Expect PRME to range from $4.76 to $17.17 through 2040. The $8.91 average target implies a +205% move from current prices. That is up +28% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The PRME price prediction for 2050 points to an average of $12.77 (low $5.75, high $27.59) — a potential gain of +337% on today's $2.92. Momentum favours further upside here.
Investing $1,000 in PRME today (≈ 342.465753 PRME) could be worth
$4,374.95
+$3,374.95 (+337%) by 2050 · US Dollar
Based on the average projected PRME price of $12.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRMEwould be worth at today's price.
$1,000 invested in PRME on Jul 31, 2025 (≈ 267.379678 PRME) would be worth
$780.75
-$219.25 (-21.9%) today · 0.78× · US Dollar
Based on a PRME entry price of $3.74 vs. today's $2.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.95 | $989.83 | -1.0% |
| 1 month ago | $3.89 | $750.64 | -24.9% |
| 3 months ago | $3.41 | $856.3 | -14.4% |
| 6 months ago | $3.8 | $768.42 | -23.2% |
| 1 year ago | $3.74 | $780.75 | -21.9% |
| All time (3.8y) ago | $15.37 | $189.98 | -81.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRME forecast.
Our base-case forecast reaches $5.80 around 2035.
Implied market cap at $5.80: $1.05B
The multi-year forecast shows a bullish trajectory beginning after 2026, with 2027 at an average of $3.42 and 2028 at $4.15, rising further through 2029 ($4.69) and 2030 ($4.76). By 2030 the forecast anticipates a 60.3% ROI with a bullish sentiment and higher price potential than the near term.
In the mid-2030s the average price climbs to $7.50 in 2035 with a 152.4% ROI, and the trend continues higher into the late 2030s and 2040s, reaching an average of $9.47 and a max of $19.48 in 2040 (ROI 218.9%), followed by an average of $13.09 and a max of $30.12 in 2050 (ROI 340.9%), with bullish sentiment.
Across these years the forecast generally assigns bullish sentiment from 2027 onward, reflecting the anticipated long-run appreciation despite near-term variability. These figures are estimates and not guarantees, reflecting the modeled outlook for the asset over a long horizon.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $4.76 with a min of $3.11 and a max of $7.89, and a ROI of 60.3% with a bullish outlook.
The near-term 2026 view is neutral with an average price of $2.97, while the outlook strengthens in later years with rising averages and ROIs, culminating in a 2050 average of $13.09 and a 340.9% ROI; these are estimates, not guarantees.
Yes. The forecast shows a max of $10.75 in 2034 and higher in later years (2035 max $14.13; 2040 max $19.48; 2050 max $30.12).
For 2040 the forecast lists an average price of $9.47, a min of $4.52, a max of $19.48, and a ROI of 218.9% with a bullish sentiment.
Prime Medicine is a biotechnology company delivering genetic medicines using gene editing technology in the United States. Its lead candidate PM359 targets Chronic Granulomatous Disease in Phase 1/2, PM577 targets Wilson Disease in preclinical studies, and PM647 targets a SERPINA1-related liver disorder. The company also pursues in vivo liver programs and Cystic Fibrosis programs, using Prime Editing technology and pegRNA. It was incorporated in 2019 and is headquartered in Cambridge, Massachusetts, with collaborations and licenses from BMS, the Cystic Fibrosis Foundation, Broad Institute, and Beam.
Prime Medicine, Inc. Community Discussion
0Share your Prime Medicine, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.